Arrhythmia

HeartBeam Reports First Quarter 2024 Results

Retrieved on: 
Jeudi, mai 9, 2024
Cardiology, Software, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Clinical Trials, FDA, Arrhythmia, Vectorcardiography, VCG, Research, United States patent law, Doctor of Philosophy, ECG, Artificial intelligence, Webcast, 3D, Intelligence, Consultant, Atrial flutter, Patient, Patent, Algorithm, Medical device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.
  • Research and development expenses for the first quarter of 2024 were $2.4 million, compared to $1.7 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $2.4 million compared to $2.5 million for the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $4.6 million, compared to a net loss of $4.1 million for the first quarter of 2023.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
Jeudi, mai 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
Jeudi, mai 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Retrieved on: 
Mercredi, mai 8, 2024
DSM-IV codes, Patient, Adolescence, Safety, Obstruction, LVEF, Risk, Pharmacokinetics, Cytokinetics, NYHA, Research and development, Arrhythmia, Mercury (element), Library classification, Heart failure, Clinical trial, Quality of life, SAN, Ageing

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.
  • Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM.
  • HCM can present similarly in adolescents and children as it does in adults and may negatively impact overall quality of life.
  • Patients will be randomized on a 2:1 basis to receive aficamten or placebo, and those receiving aficamten will begin with 5 mg dosed once daily.

Heartwarming Travel Memoir From The Perspective Of A Dog Who Cares For The Health Of Their Human Delights New Readers

Retrieved on: 
Mercredi, mai 8, 2024
Amazon (company), Nature, Social media, Service, Scotty, Health, Travel, Life, Shoulder, Hypertension, Assistance dog, Arrhythmia

The real-life ​​West Highland White Terrier acts as a loyal service dog to Ana, the book’s author and a passionate biologist who suffers from arrhythmia and hypertension.

Key Points: 
  • The real-life ​​West Highland White Terrier acts as a loyal service dog to Ana, the book’s author and a passionate biologist who suffers from arrhythmia and hypertension.
  • Without Scotty, she couldn’t follow her dreams of exploring nature and making the world a better place.
  • In The Travels of a Service Dog: Stories of Scotty, Ana writes a delightful and heartfelt account of their travels from the perspective of Scotty.
  • The Travels of a Service Dog: Stories of Scotty is available for purchase online at Amazon.com and Barnes and Noble.com .

Kardium Announces Enhanced Clinical Capabilities of the Globe® System With Right Atrial Ablation and Hybrid Energy Ablation

Retrieved on: 
Jeudi, mai 9, 2024
Cardiology, Other Health, Health, General Health, Pharmaceutical, Health Technology, Other Science, Medical Devices, Research, Hospitals, Science, Electrode, American College, AFL, Heart, CTI, Arrhythmia, Gold, Atrial flutter, Patient, RF, Mount Sinai Hospital, PVI, Inc., Atrial fibrillation, Catheter, Incidence, Medical imaging

The ablation procedures were also completed utilizing pulsed field (PF) energy, radiofrequency (RF) energy, or a hybrid combination of both, all using sedation without the need for general anesthesia.

Key Points: 
  • The ablation procedures were also completed utilizing pulsed field (PF) energy, radiofrequency (RF) energy, or a hybrid combination of both, all using sedation without the need for general anesthesia.
  • Atrial flutter, the second most common cardiac arrhythmia after atrial fibrillation, frequently accompanies atrial fibrillation.1 In the United States, about 200,000 new cases of atrial flutter arise each year, 2 with CTI-line ablation being the preferred approach to prevent atrial flutter occurrences.
  • Dr. Vivek Reddy of The Mount Sinai Hospital, New York, remarked, “Treating CTI-dependent atrial flutter with the Globe System showcases a differentiating approach in ablation catheter technology.
  • Kardium Inc. ( kardium.com ) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe® System.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
Mercredi, mai 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, Multimedia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/texas-cardiac-arrhythmia-instit...
    SOURCE Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
Mercredi, mai 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • Physicians received a maximum of 14.5 American Medical Association (AMA) Physician's Recognition Award (PRA) Category 1 Credit™ hours at the conference.

Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System

Retrieved on: 
Mercredi, mai 8, 2024
FDA, Module, Arrhythmia, Catheter ablation, Ventricular fibrillation, Map, Heart, Software, Doctor of Philosophy, FACC, Cardiology, Anatomy, Electrophysiology, Science, Patient, Acquisition, FESC, Multipolar, FHRS, FAM, Atrial fibrillation, Johnson & Johnson, Catheter, Medical imaging

IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company's leading three-dimension (3D) heart mapping system used in cardiac ablation procedures. The software features new modules including the CARTO ELEVATE™ Module and CARTOSOUND™ FAM Module, designed for efficiency, reproducibility, and accuracy for electrophysiologists performing catheter ablation procedures to treat patients with atrial fibrillation (AFib) and other arrhythmias.

Key Points: 
  • IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company's leading three-dimension (3D) heart mapping system used in cardiac ablation procedures.
  • This new version advances the CARTO™ 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilization of ultrasound technology."
  • New optional CARTO™ 3 System Version 8 modules include:
    CARTOSOUND™ FAM: the first use of an artificial intelligence algorithm, cleared by the FDA in intracardiac ultrasound for Biosense Webster.
  • "Accuracy and precision in mapping the heart when treating cardiac arrhythmias are critical for electrophysiologists, and therefore, our patients," continued Dr. Di Biase.

INHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC, PREDICTIVE, AND SCREENING CARDIAC SOLUTIONS

Retrieved on: 
Lundi, mai 6, 2024
Safety, AI, Heart, 3D, Patient, Physician, Elaia, NACO, Arrhythmia, Health, Growth, Heart failure, Medical device

CAMBRIDGE, Mass. and BORDEAUX, France, May 6, 2024 /PRNewswire/ -- inHEART, a medical device company delivering the world's most advanced, AI-driven digital twin of the heart, has raised $11M to drive commercial growth of its therapeutic software solution for cardiac ablation procedures and advance the development of its predictive cardiac models for heart failure, sudden cardiac death, and cardio-embolic stroke.

Key Points: 
  • In addition, inHEART received funds from a successful crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation.
  • "We welcome this strong international group of investors to our latest round of financing," said Todor Jeliaskov, Chairman and CEO of inHEART.
  • "This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support.
  • The inHEART solution creates highly detailed, interactive 3D heart models with proprietary AI-driven cardiac CT or MR image segmentation.